Home › GE Healthcare Files Supplemental New Drug Application For Its Own Manufacturing Of Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP)
 

Keywords :   


GE Healthcare Files Supplemental New Drug Application For Its Own Manufacturing Of Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP)

2013-01-15 13:50:00| drugdiscoveryonline News Articles

GE Healthcare recently announced that it has filed a supplemental new drug application (sNDA) that will allow the company to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), within its own facility

Tags: application files drug manufacturing

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
23.11
23.11 WEEZER / maladroit 12\"
23.11
23.11 6'1ML REV-S
23.11speak up storys
23.11190mm LS0713FL
23.11That's Moulton
23.11SEED
More »